Methylation analysis of plasma DNA informs etiologies of Epstein-Barr virus-associated diseases
W K Jacky Lam, Peiyong Jiang, K C Allen Chan, Wenlei Peng, Huimin Shang, Macy M S Heung, Suk Hang Cheng, Haiqiang Zhang, O Y Olivia Tse, Radha Raghupathy, Brigette B Y Ma, Edwin P Hui, Anthony T C Chan, John K S Woo, Rossa W K Chiu, Y M Dennis Lo, W K Jacky Lam, Peiyong Jiang, K C Allen Chan, Wenlei Peng, Huimin Shang, Macy M S Heung, Suk Hang Cheng, Haiqiang Zhang, O Y Olivia Tse, Radha Raghupathy, Brigette B Y Ma, Edwin P Hui, Anthony T C Chan, John K S Woo, Rossa W K Chiu, Y M Dennis Lo
Abstract
Epstein-Barr virus (EBV) is associated with a number of diseases, including malignancies. Currently, it is not known whether patients with different EBV-associated diseases have different methylation profiles of circulating EBV DNA. Through whole-genome methylation analysis of plasma samples from patients with nasopharyngeal carcinoma (NPC), EBV-associated lymphoma and infectious mononucleosis, we demonstrate that EBV DNA methylation profiles exhibit a disease-associated pattern. This observation implies a significant potential for the development of methylation analysis of plasma EBV DNA for NPC diagnostics. We further analyse the plasma EBV DNA methylome of NPC and non-NPC subjects from a prospective screening cohort. Plasma EBV DNA fragments demonstrate differential methylation patterns between NPC and non-NPC subjects. Combining such differential methylation patterns with the fractional concentration (count) and size of plasma EBV DNA, population screening of NPC is performed with an improved positive predictive value of 35.1%, compared to a count- and size-based only protocol.
Conflict of interest statement
Y.M.D.L. is a scientific cofounder and a member of the scientific advisory board for Grail. Y.M.D.L., R.W.K.C. and K.C.A.C. hold equity in Grail and Take2 Health, and receive research funding from Grail/Cirina. Y.M.D.L., R.W.K.C. and K.C.A.C. are cofounders and board members of DRA Company Limited. P.J. is a consultant to Grail and holds equity in Grail and is nominated as a director of KingMed Future. W.K.J.L. is a consultant to Grail and holds equity in Grail. E.P.H. receives fees for serving on an advisory board for Bristol-Myers Squibb and Merck Sharp & Dohme. Y.M.D.L., R.W.K.C., K.C.A.C., P.J. and W.K.J.L. have filed patent applications based on this work.
Figures
References
- Young LS, Yap LF, Murray PG. Epstein-Barr virus: more than 50 years old and still providing surprises. Nat. Rev. Cancer. 2016;16:789–802. doi: 10.1038/nrc.2016.92.
- Li YY, et al. Exome and genome sequencing of nasopharynx cancer identifies NF-κB pathway activating mutations. Nat. Commun. 2017;8:14121. doi: 10.1038/ncomms14121.
- Lin DC, et al. The genomic landscape of nasopharyngeal carcinoma. Nat. Genet. 2014;46:866–871. doi: 10.1038/ng.3006.
- Lo YMD, et al. Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma. Cancer Res. 1999;59:1188–1191.
- Lei KI, Chan LY, Chan WY, Johnson PJ, Lo YMD. Quantitative analysis of circulating cell-free Epstein-Barr virus (EBV) DNA levels in patients with EBV-associated lymphoid malignancies. Br. J. Haematol. 2000;111:239–246. doi: 10.1046/j.1365-2141.2000.02344.x.
- Lo YMD, et al. Circulating Epstein-Barr virus DNA in the serum of patients with gastric carcinoma. Clin. Cancer Res. 2001;7:1856–1859.
- Welch JJG, et al. Epstein-Barr virus DNA in serum as an early prognostic marker in children and adolescents with Hodgkin lymphoma. Blood Adv. 2017;1:681–684. doi: 10.1182/bloodadvances.2016002618.
- Kanakry JA, et al. Plasma Epstein-Barr virus DNA predicts outcome in advanced Hodgkin lymphoma: correlative analysis from a large North American cooperative group trial. Blood. 2013;121:3547–3553. doi: 10.1182/blood-2012-09-454694.
- Kanakry JA, et al. The clinical significance of EBV DNA in the plasma and peripheral blood mononuclear cells of patients with or without EBV diseases. Blood. 2016;127:2007–2017. doi: 10.1182/blood-2015-09-672030.
- Lo YMD, et al. Quantitative and temporal correlation between circulating cell-free Epstein-Barr virus DNA and tumor recurrence in nasopharyngeal carcinoma. Cancer Res. 1999;59:5452–5455.
- Chan ATC, et al. Plasma Epstein-Barr virus DNA and residual disease after radiotherapy for undifferentiated nasopharyngeal carcinoma. J. Natl Cancer Inst. 2002;94:1614–1619. doi: 10.1093/jnci/94.21.1614.
- Leung SF, et al. Plasma Epstein-Barr viral DNA load at midpoint of radiotherapy course predicts outcome in advanced-stage nasopharyngeal carcinoma. Ann. Oncol. 2014;25:1204–1208. doi: 10.1093/annonc/mdu117.
- Chan KCA, et al. Analysis of plasma Epstein-Barr virus DNA to screen for nasopharyngeal cancer. N. Engl. J. Med. 2017;377:513–522. doi: 10.1056/NEJMoa1701717.
- Ambinder RF. Plasma Epstein–Barr virus DNA for screening. N. Engl. J. Med. 2017;377:584–585. doi: 10.1056/NEJMe1706815.
- Wang L, et al. Post-treatment plasma EBV-DNA positivity predicts early relapse and poor prognosis for patients with extranodal NK/T cell lymphoma in the era of asparaginase. Oncotarget. 2015;6:30317–30326.
- Gulley ML, Tang W. Using Epstein-Barr viral load assays to diagnose, monitor, and prevent posttransplant lymphoproliferative disorder. Clin. Microbiol. Rev. 2010;23:350–366. doi: 10.1128/CMR.00006-09.
- Lam WKJ, et al. Sequencing-based counting and size profiling of plasma Epstein-Barr virus DNA enhance population screening of nasopharyngeal carcinoma. Proc. Natl Acad. Sci. USA. 2018;115:E5115–E5124. doi: 10.1073/pnas.1804184115.
- Ambinder RF, Robertson KD, Tao Q. DNA methylation and the Epstein–Barr virus. Semin. Cancer Biol. 1999;9:369–375. doi: 10.1006/scbi.1999.0137.
- Fernandez AF, et al. The dynamic DNA methylomes of double-stranded DNA viruses associated with human cancer. Genome Res. 2009;19:438–451. doi: 10.1101/gr.083550.108.
- Lieberman PM. Keeping it quiet: chromatin control of gammaherpesvirus latency. Nat. Rev. Microbiol. 2013;11:863–875. doi: 10.1038/nrmicro3135.
- Tempera I, Lieberman PM. Epigenetic regulation of EBV persistence and oncogenesis. Semin. Cancer Biol. 2014;26:22–29. doi: 10.1016/j.semcancer.2014.01.003.
- Woellmer A, Hammerschmidt W. Epstein-Barr virus and host cell methylation: regulation of latency, replication and virus reactivation. Curr. Opin. Virol. 2013;3:260–265. doi: 10.1016/j.coviro.2013.03.005.
- Fejer G, et al. Latency type-specific distribution of epigenetic marks at the alternative promoters Cp and Qp of Epstein-Barr virus. J. Gen. Virol. 2008;89:1364–1370. doi: 10.1099/vir.0.83594-0.
- Kanakry J, Ambinder R. The biology and clinical utility of EBV monitoring in blood. Curr. Top. Microbiol Immunol. 2015;391:475–499.
- Chiu RWK, et al. Non-invasive prenatal assessment of trisomy 21 by multiplexed maternal plasma DNA sequencing: large scale validity study. Br Med J. 2011;342:c7401. doi: 10.1136/bmj.c7401.
- Ehrich M, et al. Noninvasive detection of fetal trisomy 21 by sequencing of DNA in maternal blood: a study in a clinical setting. Am. J. Obstet. Gynecol. 2011;204:205.e1–11. doi: 10.1016/j.ajog.2010.12.060.
- Palomaki GE, et al. DNA sequencing of maternal plasma to detect Down syndrome: an international clinical validation study. Genet. Med. 2011;13:913–920. doi: 10.1097/GIM.0b013e3182368a0e.
- Church TR, et al. Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer. Gut. 2014;63:317–325. doi: 10.1136/gutjnl-2012-304149.
- Chan KCA, Chu SWI, Lo YMD. Ambient temperature and screening for nasopharyngeal cancer. N. Engl. J. Med. 2018;378:962–963. doi: 10.1056/NEJMc1800433.
- Chan ATC, et al. Azacitidine induces demethylation of the Epstein-Barr virus genome in tumors. J. Clin. Oncol. 2004;22:1373–1381. doi: 10.1200/JCO.2004.04.185.
- Mesri EA, Feitelson MA, Munger K. Human viral oncogenesis: a cancer hallmarks analysis. Cell Host Microbe. 2014;15:266–282. doi: 10.1016/j.chom.2014.02.011.
- Sozzi G, et al. Quantification of free circulating DNA as a diagnostic marker in lung cancer. J. Clin. Oncol. 2003;21:3902–3908. doi: 10.1200/JCO.2003.02.006.
- Beau-Faller M, et al. Plasma DNA microsatellite panel as sensitive and tumor-specific marker in lung cancer patients. Int. J. Cancer. 2003;105:361–370. doi: 10.1002/ijc.11079.
- Schmidt B, Weickmann S, Witt C, Fleischhacker M. Integrity of cell-free plasma DNA in patients with lung cancer and nonmalignant lung disease. Ann. N. Y. Acad. Sci. 2008;1137:207–213. doi: 10.1196/annals.1448.034.
- Jung K, et al. Increased cell-free DNA in plasma of patients with metastatic spread in prostate cancer. Cancer Lett. 2004;205:173–180. doi: 10.1016/j.canlet.2003.11.023.
- McShane LM, et al. REporting recommendations for tumour MARKer prognostic studies (REMARK) Br. J. Cancer. 2005;93:387–391. doi: 10.1038/sj.bjc.6602678.
- Lun FMF, et al. Noninvasive prenatal methylomic analysis by genomewide bisulfite sequencing of maternal plasma DNA. Clin. Chem. 2013;59:1583–1594. doi: 10.1373/clinchem.2013.212274.
- Chan KCA, et al. Noninvasive detection of cancer-associated genome-wide hypomethylation and copy number aberrations by plasma DNA bisulfite sequencing. Proc. Natl Acad. Sci. USA. 2013;110:18761–18768. doi: 10.1073/pnas.1313995110.
- Chan RWY, et al. Plasma DNA aberrations in systemic lupus erythematosus revealed by genomic and methylomic sequencing. Proc. Natl Acad. Sci. USA. 2014;111:E5302–E5311. doi: 10.1073/pnas.1421126111.
- Sun K, et al. Plasma DNA tissue mapping by genome-wide methylation sequencing for noninvasive prenatal, cancer, and transplantation assessments. Proc. Natl Acad. Sci. USA. 2015;112:E5503–E5512. doi: 10.1073/pnas.1508736112.
- Gu H, et al. Genome-scale DNA methylation mapping of clinical samples at single-nucleotide resolution. Nat. Methods. 2010;7:133–136. doi: 10.1038/nmeth.1414.
- Jiang Peiyong, Sun Kun, Lun Fiona M. F., Guo Andy M., Wang Huating, Chan K. C. Allen, Chiu Rossa W. K., Lo Y. M. Dennis, Sun Hao. Methy-Pipe: An Integrated Bioinformatics Pipeline for Whole Genome Bisulfite Sequencing Data Analysis. PLoS ONE. 2014;9(6):e100360. doi: 10.1371/journal.pone.0100360.
Source: PubMed